scispace - formally typeset
Journal ArticleDOI

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

TLDR
It is concluded that fluoride therapy increases cancellous but decreases cortical bone mineral density and increases skeletal fragility, and the fluoride-calcium regimen was not effective treatment for postmenopausal osteoporosis.
Abstract
Although fluoride increases bone mass, the newly formed bone may have reduced strength. To assess the effect of fluoride treatment on the fracture rate in osteoporosis, we conducted a four-year prospective clinical trial in 202 postmenopausal women with osteoporosis and vertebral fractures who were randomly assigned to receive sodium fluoride (75 mg per day) or placebo. All received a calcium supplement (1500 mg per day). Sixty-six women in the fluoride group and 69 women in the placebo group completed the trial. As compared with the placebo group, the treatment group had increases in median bone mineral density of 35 percent (P less than 0.0001) in the lumbar spine (predominantly cancellous bone), 12 percent (P less than 0.0001) in the femoral neck, and 10 percent (P less than 0.0001) in the femoral trochanter (sites of mixed cortical and cancellous bone), but the bone mineral density decreased by 4 percent (P less than 0.02) in the shaft of the radius (predominantly cortical bone). The number of new vertebral fractures was similar in the treatment and placebo groups (163 and 136, respectively; P not significant), but the number of nonvertebral fractures was higher in the treatment group (72 vs. 24; P less than 0.01). Fifty-four women in the fluoride group and 24 in the placebo group had side effects sufficiently severe to warrant dose reduction; the major side effects were gastrointestinal symptoms and lower-extremity pain. We conclude that fluoride therapy increases cancellous but decreases cortical bone mineral density and increases skeletal fragility. Thus, under the conditions of this study, the fluoride-calcium regimen was not effective treatment for postmenopausal osteoporosis.

read more

Citations
More filters
Journal ArticleDOI

Grading quality of evidence and strength of recommendations.

TL;DR: A system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts is developed, and a summary of the approach from the perspective of a guideline user is presented.
Journal ArticleDOI

The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials

TL;DR: The revised CONSORT statement is intended to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
Journal ArticleDOI

External validity of randomised controlled trials: “To whom do the results of this trial apply?”

Peter M. Rothwell
- 01 Jan 2005 - 
TL;DR: In this paper, the authors present a checklist for clinicians to consider external validity in the design and reporting of RCTs and make recommendations for greater consideration of external validity for clinical trials.
Journal ArticleDOI

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

TL;DR: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebra deformities, and height loss in postmenopausal women with osteoporosis.
Journal ArticleDOI

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

TL;DR: The criteria required for an effective screening strategy for osteoporosis are largely met in Caucasian women as mentioned in this paper, which suggests that it is appropriate to consider targetting of treatment with agents affecting bone metabolism to susceptible individuals.
References
More filters
Journal ArticleDOI

Effect of combined therapy with sodium fluoride, vitamin D and calcium in osteoporosis

TL;DR: In this paper, the effect of variable levels of fluoride and calcium intake, accompanied by vitamin D, on osteoporosis in eleven patients treated for one year Bone biopsies indicated an increase in new bone formation in all patients receiving 45 mg of sodium fluoride per day, whereas 600 mg of calcium per day prevented both osteomalacia and any increase in bone resorption.
Journal ArticleDOI

Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis

TL;DR: After a follow-up of 24 months the fluoride-calcium group showed a significantly lower rate of new vertebral fractures, the main adverse effect of the regimen being a higher incidence of osteoarticular pains in the ankle and foot.
Journal Article

Distribution of beta-lipoprotein between low-density and very low-density lipoproteins.

TL;DR: In order to restore bone mass in osteoporotic subjects without producing roentgenographic or microscopic evidence of fluorosis, a therapeutic regimen of 50 mg of sodium fluoride and at least 900 mg of calcium per day and 50,000 units of vitamin D twice weekly is recommended.
Related Papers (5)